Overview of α-blocker therapy for benign prostatic hyperplasia

被引：37

作者：

Narayan, P ^{[1
]}

Tewari, A ^{[1
]}

机构：

[1] Univ Florida, Coll Med, Div Urol, VAMC, Gainesville, FL 32610 USA

来源：

UROLOGY | 1998年 / 51卷 / 4A期

关键词：

D O I：

10.1016/S0090-4295(98)00054-5

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Management of benign prostatic hyperplasia (BPH) is rapidly changing. Established surgical procedures are being replaced by minimally invasive modalities such as electrovaporization and transurethral needle ablation. Improved understanding of pathophysiology and developments in molecular biology has provided drugs for alleviating the symptoms of prostatic enlargement. Currently, medical therapy is the first-line treatment modality in the management of BPH. There are two types of medical treatment available: alpha-adrenoceptor-blockers and 5-alpha-reductase inhibitors. Alpha-blockers relieve the dynamic component of obstruction whereas 5-alpha-reductase inhibitors relieve the mechanical component of obstruction. At present, alpha-blockers are used most frequently. However, they do have significant cardiovascular side effects. More uroselective alpha-blockers have recently become available and may reduce the risk of cardiovascular side effects. This review summarizes relevant literature on the use of alpha-blockers in the treatment of BPH. (C) 1998, Elsevier Science Inc. All rights reserved.

引用

页码：38 / 45

页数：8

共 58 条

[31] ALFUZOSIN FOR TREATMENT OF BENIGN PROSTATIC HYPERTROPHY [J].

JARDIN, A ;

BENSADOUN, H ;

DELAUCHECAVALLIER, MC ;

ATTALI, P .

LANCET, 1991, 337 (8755) :1457-1461

[32]

JARDIN A, 1988, ANN UROL, V22, P333

[33]

KAWABE K, 1995, BRIT J UROL, V76, P63

[34] Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: Binding, functional and in vivo studies [J].

Kenny, BA ;

Miller, AM ;

Williamson, IJR ;

OConnell, J ;

Chalmers, DH ;

Naylor, AM .

BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (04) :871-878

[35]

Khanna O P, 1975, Urology, V6, P323, DOI 10.1016/0090-4295(75)90756-6

[36] PRAZOSIN IN THE TREATMENT OF PROSTATIC OBSTRUCTION - A PLACEBO-CONTROLLED STUDY [J].

KIRBY, RS ;

COPPINGER, SWC ;

CORCORAN, MO ;

CHAPPLE, CR ;

FLANNIGAN, M ;

MILROY, EJG .

BRITISH JOURNAL OF UROLOGY, 1987, 60 (02) :136-142

[37] THE EFFICACY OF PRAZOSIN-HCL IN THE TREATMENT OF URINARY FLOW OBSTRUCTION DUE TO PROSTATIC HYPERTROPHY [J].

KONDO, A ;

GOTOH, M ;

SAITO, M ;

TAKITA, T ;

KOBAYASHI, M ;

OTANI, T ;

ITO, K .

UROLOGIA INTERNATIONALIS, 1990, 45 :4-17

[38]

Leonardi A, 1997, J PHARMACOL EXP THER, V281, P1272

[39] A RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA [J].

LEPOR, H ;

AUERBACH, S ;

PURASBAEZ, A ;

NARAYAN, P ;

SOLOWAY, M ;

LOWE, F ;

MOON, T ;

LEIFER, G ;

MADSEN, P .

JOURNAL OF UROLOGY, 1992, 148 (05) :1467-1474

[40] LONG-TERM EFFICACY AND SAFETY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA [J].

LEPOR, H .

UROLOGY, 1995, 45 (03) :406-413

← 1 2 3 4 5 6 →